e13596 Background: To explore the effect of 2 different gargles on the prevention and treatment of radioactive oral mucositis in patients with head and neck cancer, and to provide a theoretical basis for clinical prevention and treatment of radioactive oral mucositis. Methods: A total of 200 patients with head and neck malignant tumors diagnosed via pathological examination and free from distant metastasis in our head and neck on cology departmert from August 2022 to November 2024 were selected as the research subjects,and according to the sequence of admission, they were allocated into an observation group (biopolysaccharide body therapy) and a control group (conventional fluid therapy)using a randomized number table. Both cohorts underwent radical intensity⁃modulated radiotherapy and were administered medications aimed at preventing mucositis throughout the radiotherapy period, concluding upon treatment completion. Using the American Radiation Oncology Collaboration Group's grading criteria for oral mucositis and the numeric rating scale for pain scoring,the extent of oral mucositis, oral pain, and xerostomia experienced by patients in both groups was assessed. Results: Both cohorts exhibited varying severities of radiation⁃induced oral mucositis, xerostomia, and oropharyngeal discomfort. In comparison to the control group, the severity of radiation⁃induced oral mucositis was mitigated and the onset of symptoms was delayed as well as the incidence of xerostomia was decreased in the experimental group,and no significant adverse drug reactions were reported among all enrolled patients, and these findings demonstrated statistical significance (P < 0.05). Conclusions: Both biopolysaccharide bodies andKangfuxin solution have a certain effect on the protection of radioactive oral mucositis, but the clinical treatment effect of biopolysaccharide bodies is better. There are no adverse reactions related to drugs, which is worthy of clinical application. Comparison of radiation-related oral toxicities between two groups. Outcome Control (n=100) Observation (n=100) Statistics P value Grade 2 oral mucositis, n (%) 53 (53.0) 35 (35.0) χ² = 16.17 ＜0.01 Grade 3 oral mucositis, n (%) 27 (27.0) 13 (13.0) χ² = 4.72 0.03 Xerostomia severity Distribution across grades Distribution across grades χ² = 42.590 0.008 Oral mucositis pain severity Distribution across grades Distribution across grades Z = 3.258 0.001 Time to grade III mucositis (days, mean ± SD) 24.2 ± 5.5 28.8 ± 6.4 t = −6.46 0.030 Time to grade IV mucositis (days, mean ± SD) 30.4 ± 3.6 38.0 ± 2.8 t = −16.47 0.219
Feng et al. (Thu,) studied this question.